

4.0.03 DOC Cmte minutes

Autism Spectrum Disorder Committee meeting

Date: 4 September 2017

Location: NICE office, Manchester

Minutes: Final



Committee members present:		
Tessa Lewis (Chair) (TL)		(Present for notes 1 – 6)
Gillian Baird (topic expert) (GB)		(Present for notes 1 – 6)
Tony Charman (topic expert) (TC)		(Present for notes 1 – 6)
Jenny Drew (topic expert) (JD)		(Present for notes 1 – 6)
Clare Jenkins (topic expert) (CJ)		(Present for notes 1 – 6)
Jennifer Leavesley (topic expert) (JL)		(Present for notes 1 – 6)
Sharon Richman (topic expert) (SR)		(Present for notes 1 – 6)
David Spitzer (topic expert) (DS)		(Present for notes 1 – 6)
Hana Whitty (topic expert) (HW)		(Present for notes 1 – 6)
John Cape (JC)		(Present for notes 1 – 6)
Alison Eastwood (AE)		(Present for notes 1 – 6)
Sarah Fishburn (SF)		(Present for notes 1 – 6)
Catriona McDaid (CM)		(Present for notes 1 – 6)
Sophie Wilne (SW)		(Present for notes 1 – 6)

In attendance:		
Caroline Keir (CK)	Guideline Commissioning Manager – NICE	(Present for notes 1 – 6)
Yolanda Martinez (YM)	Technical Analyst – GUT	(Present for notes 1 – 6)
Adam O’Keefe (AO)	Project Manager – GUT	(Present for notes 1 – 6)
Joshua Pink (JP)	Technical Adviser – GUT	(Present for notes 1 – 6)
Sue Spiers (SS)	Associate Director – GUT	(Present for notes 1 – 6)
Adam Storrow (AS)	Business Analyst – NICE	(Present for notes 1 – 6)

Observers:		
Rachel Gick – Information Specialist, NICE		
Erin Whittingham – Public Involvement Adviser, NICE		

4.0.03 DOC Cmte minutes

Apologies:	
Gail Fortes-Mayer	Standing Committee member
Victoria Hetherington	Standing Committee member
Imran Jawaid	Standing Committee member
Nick Screaton	Standing Committee member

1. Welcome and objectives for the meeting

The Chair welcomed the committee members and attendees to the first Guideline Updates meeting on Autism Spectrum Disorder. The Chair invited the committee members and attendees to introduce themselves.

There were two observers from NICE at the meeting.

The Chair informed the committee that apologies had been received as noted above.

The Chair outlined the objectives of the meeting, which were the presentation of clinical evidence and drafting of recommendations for two review questions and an update of terminology.

The Chair confirmed that, for the purpose of managing conflicts of interest, the matter under discussion was whether certain risk factors and disorders increased the likelihood of a diagnosis of autism spectrum disorder and assist in the decision to refer for a formal autism diagnostic assessment in children and young people under 19.

The Chair asked those present to verbally declare any interests that have arisen since the last meeting. No new interests were declared. Having reviewed the registry of historical declarations, the Chair declared that all attendees could fully participate in the meeting.

2. Topic Introduction

YM presented a brief introduction to the topic. YM then invited JD and JL to give short presentations on their experiences as lay members. The Chair invited the committee to ask the topic experts questions about the topic.

3. Presentations

YM provided the committee with a summary of key terminology to aid their understanding of the evidence presentation. YM then presented the clinical evidence for the update. The committee and experts were reminded that they all agreed to and signed off the review protocol for the update at the beginning of the process. The

4.0.03 DOC Cmte minutes

committee and experts discussed the clinical evidence.

There was no health economic evidence identified for this topic.

4. Resource Impact Presentation

The Chair introduced AS as the Resource Impact Assessment (RIA) lead on the guideline, who explained the role of the Business Analyst and answered the committee's questions around this.

5. Discussion and recommendations

The committee considered the following equalities issues:

- Age, gender reassignment, pregnancy and maternity, socio-economic status, sex, religion or belief, race, sexual orientation, disability.

The committee considered the new evidence and agreed to update the original recommendations to reflect this. The committee then discussed and agreed updates to terminology used in several areas of the guideline.

6. Next steps

AO provided the committee key dates for the next phase in this guideline update.

The Chair thanked the committee and closed the meeting.

Date of next meeting: 16th November 2017

Location of next meeting: Manchester NICE office